PUBLISHER: The Business Research Company | PRODUCT CODE: 1825771
PUBLISHER: The Business Research Company | PRODUCT CODE: 1825771
Immunoglobulin E (IgE) allergy blood tests are designed to measure the levels of IgE antibodies present in the bloodstream, which are generated by the immune system in response to allergens. These tests play a crucial role in identifying the particular allergens responsible for triggering allergic reactions in individuals. Healthcare providers rely on these test results to pinpoint the allergens causing allergic symptoms, enabling them to tailor treatment plans accordingly and thereby improving patient management and overall quality of life.
The primary product categories of IgE allergy blood tests include assays and kits, which comprise enzyme-linked immunosorbent assay (ELISA) testing kits, fluorescent enzyme immunoassays (FEIA) testing kits, and chemiluminescent immunoassays (CLIA). These kits and assays consist of tools and substances utilized to analyze biological samples for specific allergens or conditions. They serve diverse applications, encompassing aero allergies, indoor allergies, outdoor allergies, food allergies, venoms, medicine allergies, and latex/metal allergies. End users of these products span diagnostic laboratories, specialty clinics, hospitals, and research and academic centers, reflecting a wide array of healthcare and scientific facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The immunoglobulin E (IgE) allergy blood tests market research report is one of a series of new reports from The Business Research Company that provides immunoglobulin E (IgE) allergy blood tests market statistics, including the immunoglobulin E (IgE) allergy blood tests industry global market size, regional shares, competitors with immunoglobulin E (IgE) allergy blood tests market share, detailed immunoglobulin E (IgE) allergy blood tests market segments, market trends, and opportunities, and any further data you may need to thrive in the immunoglobulin E (IgE) allergy blood tests industry. This immunoglobulin E (IgE) allergy blood tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The immunoglobulin e (ige) allergy blood tests market size has grown strongly in recent years. It will grow from $33.24 billion in 2024 to $36.06 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to technological advancements, increasing allergy prevalence, growing demand for personalized medicine, expanding healthcare infrastructure, and rising awareness about allergy diagnosis and treatment.
The immunoglobulin e (ige) allergy blood tests market size is expected to see strong growth in the next few years. It will grow to $48.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising investments in allergy research and development, expanding adoption of point-of-care testing, increasing focus on early diagnosis and intervention, growing demand for comprehensive allergy profiling, and integration of artificial intelligence in allergy diagnostics. Major trends in the forecast period include emergence of multiplex allergy testing, utilization of telemedicine for allergy consultations, development of novel biomarkers for allergic diseases, expansion of direct-to-consumer allergy testing services, and integration of big data analytics for personalized allergy management.
The forecast of 7.8% growth over the next five years reflects a modest reduction of 0.7% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of IgE-specific immunoassay kits sourced from Germany and Japan, thereby delaying allergy diagnosis and elevating immunology lab expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growing prevalence of allergies is expected to drive the growth of the IgE allergy blood tests market in the coming years. Allergies occur when the immune system reacts excessively to substances that are usually harmless to most people, leading to symptoms such as sneezing, itching, and respiratory problems. The rise in allergy cases can be attributed to lifestyle changes, environmental pollution, and genetic factors. IgE allergy blood tests are used to identify specific allergens by measuring the levels of Immunoglobulin E (IgE) antibodies in the blood, which helps in diagnosing and managing allergic conditions like asthma, allergic rhinitis, and food allergies. For example, according to the AAFA 2022 Allergy Capitals Report released by the Asthma and Allergy Foundation of America in March 2022, seasonal allergic rhinitis, commonly known as hay fever, is among the most widespread allergic conditions. Approximately 7.7% of adults and 7.2% of children have been diagnosed with this condition. Thus, the increasing prevalence of allergies is fueling the growth of the IgE allergy blood tests market.
Innovations in the IgE allergy blood test market focus on developing AI-powered allergy tests to enhance accuracy, efficiency, and scalability in allergy diagnostics. These tests leverage artificial intelligence algorithms and machine learning techniques to analyze allergy-related data and provide valuable insights into individual allergic sensitivities. For example, Dr. Dangs Lab introduced 'Allergynius Dx,' a molecular allergy diagnostics test based on Microarray using Nano Particles, capable of testing 163 food and respiratory allergens. This advancement signifies a significant leap in allergy testing, offering a comprehensive approach to identifying and managing allergies across a broad spectrum of allergens.
In October 2022, Sebia, a France-based provider of equipment and reagents for clinical protein electrophoresis, acquired Zeus Scientific Inc. for an undisclosed amount. This acquisition is intended to enhance Sebia's product range and expand its market footprint in the United States. By incorporating Zeus Scientific's expertise in immunofixation electrophoresis and related diagnostics, Sebia aims to strengthen its portfolio within the clinical laboratory sector. Zeus Scientific Inc. is a US-based manufacturer of medical equipment.
Major companies operating in the immunoglobulin E (IgE) allergy blood tests market are Roche Holdings Inc., Thermo Fisher Scientific Inc, Abbott Laboratories, Novartis AG, Siemens Healthineers Pvt Ltd, BD Biosciences, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, BioMerieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Bio-Techne Corporation, GenScript Biotech Corporation, Randox Laboratories Ltd, Neogen Corporation, Invitae Corporation, Quanterix Corporation, Omega Diagnostics Plc, AESKU Group GmbH, Hitachi Chemical Diagnostics Inc., HYCOR Biomedical LLC, Amerimmune LLC
North America was the largest region in the immunoglobulin E (IgE) allergy blood tests market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin E (IgE) allergy blood tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the immunoglobulin E (IgE) allergy blood tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The immunoglobulin E (IgE) allergy blood tests market consists of sales of custom panels, and component-resolved diagnostics (CRD). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Immunoglobulin E (IgE) Allergy Blood Tests Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on immunoglobulin e (ige) allergy blood tests market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for immunoglobulin e (ige) allergy blood tests ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The immunoglobulin e (ige) allergy blood tests market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.